Several FDA Approval Boosting the Growth of Global NT Growth Factor Receptor Market

Published: Apr 2022

The global NT growth factor receptor market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, new product launches, FDA approval, research, and development of new drugs to stay competitive in the market. For instance, in May 2021, FDA grants approval to amivantamab-vmjw, which is a bi-specific antibody directed against epidermal growth factor and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptors.

Browse the full report description “Global NT Growth Factor Receptor Market Size, Share & Trends Analysis Report By Type (AZD-7451, Larotrectinib, DS-6051, LM-22B10, and Others), and By Application (Breast Cancer, Brain Cancer, Solid Tumor, Colon Cancer, Fibrosarcoma, and Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/nt-growth-factor-receptor-market

Moreover, in May 2020, FDA approved selpercatinib, to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer. in May 2020, FDA also approved Pemazyre as the drug to treat adults with locally advanced, previously treated, advanced cholangiocarcinoma with tumors containing a fusion or other rearrangement of the fibroblast growth factor receptor 2 gene. In November 2018, FDA approved larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation.

Market Coverage

  • The market number available for – 2022-2028
  • Base year- 2022 
  • Forecast period- 2022-2028

Segment Covered- 

  • By Type
  • By Application

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape - AstraZeneca, Daiichi Sankyo Co. Ltd., HANDOK Inc., Ignyta Inc., Loxo Oncology, and others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global NT Growth Factor Receptor Market Report Segment

By Type

  • AZD-7451
  • Larotrectinib
  • DS-6051
  • LM-22B10
  • Others

By Application

  • Breast cancer
  • Brain cancer
  • Solid tumor
  • Colon cancer
  • Fibrosarcoma
  • Others

Global NT Growth Factor Receptor Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/nt-growth-factor-receptor-market